A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis

Basit Öğe Kaydı
dc.contributor.authorYurdaydin, C.
dc.contributor.authorBozkaya, H.
dc.contributor.authorKaraaslan, H.
dc.contributor.authorOender, F. O.
dc.contributor.authorErkan, Oe. E.
dc.contributor.authorYalcin, K.
dc.contributor.authorDegertekin, H.
dc.date.accessioned2024-04-24T17:11:30Z
dc.date.available2024-04-24T17:11:30Z
dc.date.issued2007
dc.departmentDicle Üniversitesien_US
dc.description.abstractHigh dose interferon treatment for 1 year is the only established treatment for chronic hepatitis D, but it is associated with a high relapse rate after treatment discontinuation. In this study, patients were treated with 10 MU interferon alpha 2b, thrice weekly for 2 years. Twenty-three patients were recruited and 15 completed the 2-year treatment and 6 months follow-up periods. Treatment response was assessed biochemically [normal alanine aminotransferase (ALT)], virologically (undetectable hepatitis D virus RNA) and histologically (at least 2 point decrease in the Knodell score) at the end of treatment (EOT) and at the end of follow-up. Out of 15 patients who finished the 2-year treatment period, seven patients (47%) had a biochemical response but only two (13%) had a normal ALT after follow-up. ALT decreased from the baseline value of 143.1 +/- 121.7 (mean +/- SD) to 39.7 +/- 20.6 (P < 0.01) at EOT. Virological response was observed in six patients at EOT and in two patients at follow-up. Two patients lost hepatitis B surface antigen. Of the 12 patients with paired liver biopsies, a histological improvement was observed in eight patients. Interferon treatment leads to a complete or partial response in a substantial number of patients but 2 years of treatment does not appear to increase sustained response rates over 1 year treatment.en_US
dc.identifier.doi10.1111/j.1365-2893.2007.00875.x
dc.identifier.endpage816en_US
dc.identifier.issn1352-0504
dc.identifier.issue11en_US
dc.identifier.pmid17927618
dc.identifier.scopus2-s2.0-35248877520
dc.identifier.scopusqualityQ2
dc.identifier.startpage812en_US
dc.identifier.urihttps://doi.org/10.1111/j.1365-2893.2007.00875.x
dc.identifier.urihttps://hdl.handle.net/11468/17566
dc.identifier.volume14en_US
dc.identifier.wosWOS:000250272500008
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherBlackwell Publishingen_US
dc.relation.ispartofJournal of Viral Hepatitis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChronic Delta Hepatitisen_US
dc.subjectTreatmenten_US
dc.subjectTwo Years Of Interferonen_US
dc.titleA pilot study of 2 years of interferon treatment in patients with chronic delta hepatitisen_US
dc.titleA pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize